Wednesday, December 22, 2021

US Army Creates Single Vaccine Against All COVID & SARS Variants, Researchers Say

Within weeks, scientists at the Walter Reed Army Institute of Research expect to announce that they have developed a vaccine that is effective against COVID-19 and all its variants, even Omicron, as well as from previous SARS-origin viruses that have killed millions of people worldwide.

Very early on, Walter Reed's infectious diseases branch decided to focus on making a vaccine that would work against not just the existing strain but all of its potential variants as well.

Walter Reed's Spike Ferritin Nanoparticle COVID-19 vaccine, or SpFN, completed animal trials earlier this year with positive results.

Phase 1 of human trials, which tested the vaccine against Omicron and the other variants, wrapped up this month, again with positive results that are undergoing final review, Dr. Kayvon Modjarrad, director of Walter Reed's infectious diseases branch, said in an exclusive interview with Defense One.

Unlike existing vaccines, Walter Reed's SpFN uses a soccer ball-shaped protein with 24 faces for its vaccine, which allows scientists to attach the spikes of multiple coronavirus strains on different faces of the protein.

Related articles 'This May Not Be The Big One': Army Scientists Warn of Deadlier Pandemics to Come The vaccine's human trials took longer than expected, he said, because the lab needed to test the vaccine on subjects who had neither been vaccinated nor previously infected with COVID. Increasing vaccination rates and the rapid spread of the Delta and Omicron variants made that difficult.

"We need to evaluate it in the real-world setting and try to understand how does the vaccine perform in much larger numbers of individuals who have already been vaccinated with something else initiallyor already been sick," Modjarrad said, adding that the new vaccine will still need to undergo phase 2 and phase 3 trials.

https://www.defenseone.com/technology/2021/12/us-army-creates-single-vaccine-effective-against-all-covid-sars-variants/360089/ 

No comments: